Shoko Nishizono
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Shoko Nishizono has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Hiroshi Sameshima
Department of Obstetrics and Gynecology, Faculty of Medicine University of Miyazaki Miyazaki Japan
1 shared publication - Masanao Ohashi
Department of Obstetrics and Gynecology Kawakita General Hospital Tokyo Japan
1 shared publication - Masatoshi Yamaguchi
Division of Clinical Genetics, University of Miyazaki, Miyazaki, Japan
1 shared publication - Munetoshi Miyatake
Faculty of Engineering, University of Miyazaki University of Miyazaki Miyazaki Japan
1 shared publication Ruriko Maruyama
Department of Obstetrics and Gynecology University of Miyazaki, Faculty of Medicine Miyazaki Japan
1 shared publication- Taichi Kobayashi
Division of Oral and Maxillofacial Radiology, Graduate School of Medical and Dental Sciences, Niigata University
1 shared publication
Latest Publications
- 17 October 2024
- Published by Wiley in Journal of Obstetrics and Gynaecology Research
- Vol. 50 (12) , 2299-2308
Citrus tamurana Hort. ex Tanaka (Hyuganatsu orange)‐derived arabinogalactan suppresses bone turnover in postmenopausal women: A randomized placebo‐controlled study
Aim: To evaluate Hyuganatsu oranges (Citrus tamurana Hort. Ex Tanaka) derived arabinogalactan for bone turnover, we performed a randomized placebo‐controlled trial.Methods: Sixty‐three postmenopausal women were age‐stratified and randomly assigned to receive arabinogalactan‐rich hyuganatsu juice (study group) or a placebo drink (control group) for 90 days. We measured blood tartrate‐resistant acid phosphatase 5b (TRACP5b), type I procollagen N‐terminal propeptide (P1NP), and other bone turnover biomarker levels at baseline, days 45 and 90 (T90) of the intervention, and day 30 of recovery. Cumulative effects were compared between groups using repeated‐measures linear mixed model analysis. The primary endpoint was the difference between the pre‐ and post‐intervention TRACP5b and P1NP levels.Results: Using repeated measures linear mixed model analysis, the study group had significantly lower TRACP5b and P1NP levels at day 90 than the control group (mean [95% confidence interval]; TRACP5b: 310.0 [269.2–350.9] vs. 386.4 [341.2–431.6] mU/dL; P1NP: 53.7 [48.6–58.7] vs. 70.3 [64.1–76.4] ng/mL), whereas other biomarker levels showed no change.Conclusion: Arabinogalactan‐rich Hyuganatsu juice suppressed bone mineral turnover and potentially improved ovarian hormone deficiency‐induced osteoporosis in postmenopausal women.
- 17 October 2024
- Published by Wiley in Journal of Obstetrics and Gynaecology Research
- Vol. 50 (12) , 2299-2308
Citrus tamurana Hort. ex Tanaka (Hyuganatsu orange)‐derived arabinogalactan suppresses bone turnover in postmenopausal women: A randomized placebo‐controlled study
Aim: To evaluate Hyuganatsu oranges (Citrus tamurana Hort. Ex Tanaka) derived arabinogalactan for bone turnover, we performed a randomized placebo‐controlled trial.Methods: Sixty‐three postmenopausal women were age‐stratified and randomly assigned to receive arabinogalactan‐rich hyuganatsu juice (study group) or a placebo drink (control group) for 90 days. We measured blood tartrate‐resistant acid phosphatase 5b (TRACP5b), type I procollagen N‐terminal propeptide (P1NP), and other bone turnover biomarker levels at baseline, days 45 and 90 (T90) of the intervention, and day 30 of recovery. Cumulative effects were compared between groups using repeated‐measures linear mixed model analysis. The primary endpoint was the difference between the pre‐ and post‐intervention TRACP5b and P1NP levels.Results: Using repeated measures linear mixed model analysis, the study group had significantly lower TRACP5b and P1NP levels at day 90 than the control group (mean [95% confidence interval]; TRACP5b: 310.0 [269.2–350.9] vs. 386.4 [341.2–431.6] mU/dL; P1NP: 53.7 [48.6–58.7] vs. 70.3 [64.1–76.4] ng/mL), whereas other biomarker levels showed no change.Conclusion: Arabinogalactan‐rich Hyuganatsu juice suppressed bone mineral turnover and potentially improved ovarian hormone deficiency‐induced osteoporosis in postmenopausal women.